Protocol Ledger

NCT05896124 · Phase II · ACTIVE NOT RECRUITING

CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)

Interventional Phase II clinical trial protocol NCT05896124 sponsored by Cascade Pharmaceuticals in Gastroenterology, Hepatology, and Renal, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-08-07 Enrollment: 75 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05896124
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)75 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05896124
Protocol FieldVerified Registry Value
NCT IdentifierNCT05896124
Consolidated Lead SponsorCascade Pharmaceuticals
Therapeutic Condition CohortGastroenterology, Hepatology, and Renal
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment75 participants (ACTUAL)
Registered Start Date2023-08-07
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05896124
Hospital Research SiteLocationSite Profile
Peking Union Medical College HospitalBeijing, ChinaOpen Hospital Dossier ->
Henan Provincial People's HospitalZhengzhou, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Gastroenterology, Hepatology, and Renal Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI